盐皮质激素受体拮抗剂用于非糖尿病肾病
本文综述了盐皮质激素受体拮抗剂(MRA)在非糖尿病慢性肾脏病(CKD)中的临床前与临床证据。临床前研究显示MRA通过抑制炎症、纤维化及氧化应激等机制保护肾脏与心血管结构,但甾体类MRA因高钾血症风险限制其临床应用;新一代非甾体MRA的临床试验正在评估其安全性与疗效。
要点
- 临床前研究显示MRA可减少蛋白尿、保护肾功能并改善心血管结局。
- 甾体类MRA在高钾血症风险下限制了非糖尿病CKD患者的临床应用。
- 非甾体MRA的临床试验正在评估其减少高钾血症且保留心肾获益的潜力。
核心结论
- 临床前证据支持MRA通过抗炎、抗纤维化及改善血流动力学等机制对非糖尿病肾病发挥心肾保护作用。
- 甾体类MRA因高钾血症风险难以在非糖尿病CKD患者中转化应用,非甾体MRA的临床试验正在评估其安全性及疗效。
研究设计与样本
- 本文为综述,汇总了非糖尿病CKD动物模型及非糖尿病晚期CKD患者的临床研究证据。
主要发现
- 在非糖尿病CKD动物模型中,MRA可防止肾脏结构损伤、减少白蛋白尿并保护肾功能。
- MRA在动物模型中还表现出预防心脏纤维化、灌注不足及血管钙化等心血管益处。
- 甾体类MRA因高钾血症风险禁忌用于CKD患者,导致临床研究缺乏。
临床怎么用
- 非糖尿病CKD患者使用MRA需权衡高钾血症风险与潜在心肾获益。
- 非甾体MRA可能减少高钾血症发生并保留心肾保护作用,但需等待临床试验结果。
局限性
- 缺乏针对非糖尿病CKD患者使用甾体类MRA的临床疗效研究。
- MRA在高钾血症风险方面的安全性问题尚未在晚期非糖尿病CKD患者中充分解决。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The use of mineralocorticoid receptor antagonists (MRAs) in preclinical models of non-diabetic chronic kidney disease (CKD) has consistently shown a beneficial effect by preventing renal structural injury, reducing albuminuria and preserving renal function. In this context, MR activation in non-epithelial cells contributes to renal injury through the activation of inflammatory and fibrotic pathways, increasing oxidative stress and modulating renal hemodynamics. The protective effects of MRAs in animal models of CKD are not restricted to the kidney. Cardiovascular benefits, such as the prevention of cardiac fibrosis, hypoperfusion and vascular calcification, have also been observed. The translation of these preclinical findings into clinical practice has been difficult, mainly due to the lack of clinical studies testing the efficacy of steroidal MRAs in CKD patients due to their contraindication because of an increased risk of hyperkalemia in these patients. Here, we review the latest preclinical evidence showing new mechanisms by which MR inhibition results in beneficial effects against cardiorenal damage in non-diabetic kidney disease. Moreover, we summarize the clinical trials testing the safety and efficacy of steroidal and non-steroidal MRAs in patients with advanced non-diabetic CKD. PLAIN ENGLISH SUMMARY: The mineralocorticoid receptor (MR) is known for its role in the regulation of sodium and potassium balance in the distal tubules of the kidney. However, under pathological conditions the activation of the MR in other renal cell types (including the vasculature and immune cells) leads to harmful effects, damaging the main structural components of the kidney, and ultimately causing renal dysfunction. Over the past 20 years, several studies performed in mouse and rat models of non-diabetic kidney disease have shown that using a specific drug class that inhibits the MR (MR antagonists: MRAs) positively impacts the preservation of the kidney structure and helps to prevent the decline of renal function, thus positioning MRAs as a good therapeutic option against kidney diseases from non-diabetic origin. In addition, the use of MRAs also benefited the cardiovascular system health as shown by improved cardiac structural and functional parameters as well as preventing the calcification of blood vessels. Nevertheless, an important barrier to translating these findings into clinical practice is that the use of MRAs could lead to increased serum potassium levels, particularly in kidney disease patients, an adverse effect that could lead to life-threatening cardiac arrhythmias. In this review, we summarize the latest data in animal models showing new evidences of MR benefits in non-diabetic kidney disease. In addition, we review the clinical trials that evaluated the safety and efficacy of MRAs in patients with advanced non-diabetic kidney disease including those that tested a new generation of MRAs (non-steroidal MRAs) and are expected to reduce the frequency of adverse effects while retaining their renal and cardiovascular benefits.
引用
- Jaisser F, Barrera-Chimal J. Mineralocorticoid receptor antagonism for non-diabetic kidney disease. Nephrol Dial Transplant. 2025. PMID: 39907538. doi:10.1093/ndt/gfae241
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。